Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. - Wikidata - wikimedia - TriplyDB

Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections.

Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections.

http://www.wikidata.org/entity/Q36287998

about

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates In vitro and in vivo antibiofilm activity of a coral associated actinomycete against drug resistant Staphylococcus aureus biofilms.Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin.In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains.Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections.Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis.Predictors of relapse of methicillin-resistant Staphylococcus aureus bacteremia after treatment with vancomycin Co-blockade of mecR1/blaR1 signal pathway to restore antibiotic susceptibility in clinical isolates of methicillin-resistant Staphylococcus aureus.Predictors of mortality in Staphylococcus aureus Bacteremia The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients.Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection Current challenges in treating MRSA: what are the options?Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006.Screening and detection of heterogenous vancomycin intermediate Staphylococcus aureus in Hospital Kuala Lumpur Malaysia, using the glycopeptide resistance detection Etest and population analysis profiling.Prophylactic intrawound application of vancomycin powder in instrumented spinal fusion surgery.Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy.Impact of switching from intravenous to oral linezolid therapy in Japanese patients: a retrospective cohort study.Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus.Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem An outbreak of heterogeneous glycopeptide-intermediate Staphylococcus aureus related to a device source in an intensive care unit.

P2860

Q24646677-3C6C3DCD-0795-4200-9C51-0C1FBEFC9720 Q26796560-068E38DC-74DA-4C53-950E-31032F6E0105 Q33656766-C1658863-3E96-46FC-ABFB-79FA83A5B8F8 Q33704710-1450B1E0-E77B-45BC-9CE0-8751E344D453 Q33876626-E34AE752-5C92-4009-93FD-9506ECD85572 Q33939095-0F016412-6A9A-4951-A86D-F830443433BD Q33945397-B75417C5-C0CA-4312-A992-93AA591695F2 Q34108614-1C1E33A0-45EE-4F8C-A753-3898B4FD84BE Q34454418-C0DB5B92-B839-4A0A-934B-7738020C8EFB Q35273507-A5EBF6C6-EB41-410A-AA85-F83B78C6AC7F Q35674145-7D060763-37BF-4202-9137-EDFA9C2A1592 Q35940556-C43B95DC-DA24-466A-A9E4-55A98EA99A90 Q36148828-1287BA5A-2508-458A-9404-A4F7B196BC89 Q36171683-54A9CC9A-1AB2-4456-83FA-8E397FF75525 Q36565462-8A056721-6945-432A-B547-E4E793184030 Q36636699-7EB16798-3C9C-4188-B036-AADC6D1C1492 Q37124131-66B6BAF0-E522-4CEB-8026-5B93C35A9979 Q37291338-2B2B975B-3D93-41C9-A1DA-E8083DB2F935 Q37392917-A8B50458-4582-4B43-BFBD-E6782404FA3D Q37482046-7471BB9B-256C-46AE-A592-35AF361CE4E3 Q37616095-9DFFC0D7-F610-427D-987C-78B61A92A539 Q37809666-323BF82A-8D7A-4154-966D-034F726934A5 Q37981103-70D8129C-51CE-41CF-BC71-ECFC609CDD6C Q37982066-DA9ABFE9-5CA8-4A35-883F-EA996BCB5258 Q41604542-E8F72D72-E0A3-41C3-B39A-EA9E1B56B0F7 Q41873909-54EFB678-C60A-416B-91ED-DF02610B50A3 Q41877894-ECC49550-7726-473B-A8C5-5FF705B8EF0A Q42049579-4B94C7C2-0426-455F-8B02-E5F09DDCB0E5 Q42111612-BEB482B9-C9F0-48F9-8CBE-742B68DCCA7B Q50977525-DF9E86E2-262F-40C3-BB3D-7D0D6C539478

P2860

Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections.

http://www.wikidata.org/entity/Q36287998

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Impact of reduced vancomycin s ...... f MRSA bloodstream infections.

@ast

Impact of reduced vancomycin s ...... f MRSA bloodstream infections.

@en

type

label

Impact of reduced vancomycin s ...... f MRSA bloodstream infections.

@ast

Impact of reduced vancomycin s ...... f MRSA bloodstream infections.

@en

prefLabel

Impact of reduced vancomycin s ...... f MRSA bloodstream infections.

@ast

Impact of reduced vancomycin s ...... f MRSA bloodstream infections.

@en

P1433

Q36287998-06EA69C0-0865-425B-ACA8-991C5DF7660F

P1476

Q36287998-AA6BE56D-686A-459F-963C-B7522CD821DB

P2093

Q36287998-4F7195EE-A7F8-4BD3-8CB5-88E5B56AF9CD

Q36287998-83A4A0C3-DFD1-4273-9E45-E1415CDEAB37

Q36287998-9F125756-A064-47A5-804A-BA04A6329048

Q36287998-E4EA0B50-8959-4CF3-9E71-B85C7F14F67B

Q36287998-F05EB66B-21AF-44C1-A10B-D38C119C46BE

Q36287998-FBA3FDA5-37C1-4D7E-BEFD-079D6EAEDBC2

P2860

Q36287998-0D711AAE-B63A-45BA-A32C-F199CB5C9A34

Q36287998-1B723B1C-1618-4B6A-8142-87104EAD7609

Q36287998-64303898-F622-4A53-AF4E-9D4AEBA4F8C4

Q36287998-7D947C6E-5A01-4EB9-9381-B13E21D171F0

Q36287998-8EA971E9-7276-4C77-A0EF-734AE6BE0845

Q36287998-9923ECAB-DBAF-48CE-85D3-0078A8D83FEF

Q36287998-AC03243C-8DA1-4A25-967F-AA7C7BCBF548

Q36287998-B82C8864-5A3B-490E-A3E4-C24880E909B4

Q36287998-C7F18F65-C5EF-4DBB-B642-9315F4C24A44

Q36287998-D8570144-A2F4-4C45-8AB1-F0F60C761D6D

P2888

Q36287998-0763069D-054F-42B8-B062-6262C8F4A636

P304

Q36287998-3646CE30-E071-4801-9F75-E837365E3944

P31

Q36287998-E5122A5D-2CE8-4DF7-8096-CF96A189AAD9

P356

Q36287998-05576BA1-6B7C-45CF-824D-1C5866B5630C

P478

Q36287998-6AA72BB3-9E45-456F-86D9-2C56670460B9

P50

Q36287998-905B9D15-0D1F-4A23-A227-C12E60117133

P577

Q36287998-3130C9E8-7EE9-4130-9E85-21406F203003

P5875

Q36287998-A142888F-DABD-4804-9463-9B54E53ACC8C

P6179

Q36287998-368D002F-5240-4FFD-AA2D-C68F448BDF83

P698

Q36287998-5A302409-C433-413F-A28C-D9159883FBF6

P932

Q36287998-1E553615-1A82-4E0F-AD93-843E090A21A7

P356

P1433

Annals of Clinical Microbiology and Antimicrobials

P1476

Impact of reduced vancomycin s ...... of MRSA bloodstream infections

@en

P2093

Fumihiko Takeuchi

http://www.w3.org/2001/XMLSchema#string

Keiichi Hiramatsu

http://www.w3.org/2001/XMLSchema#string

Longzhu Cui

http://www.w3.org/2001/XMLSchema#string

Mitsutaka Komatsu

http://www.w3.org/2001/XMLSchema#string

Satoshi Hori

http://www.w3.org/2001/XMLSchema#string

Toyoko Oguri

http://www.w3.org/2001/XMLSchema#string

P2860

ASA physical status classifications: a study of consistency of ratings

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

Glycopeptide resistance in Staphylococcus aureus: is it a real threat?

Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus.

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.

A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

[Examination of factors affecting efficacy and adverse effect, for the retrospective study of vancomycin hydrochloride (VCM)].

Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin.

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

P2888

P304

13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-0711-6-13

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5879367

http://www.w3.org/2001/XMLSchema#string

P6179

1022181666

http://www.w3.org/2001/XMLSchema#string

P698

17967199

http://www.w3.org/2001/XMLSchema#string

P932

2148052

http://www.w3.org/2001/XMLSchema#string